BRCA1 and neoplasm: In the present study, we proposed a workflow for the analysis of tumor BRCA1/2 status in all patients with a diagnosis of nonmucinous and nonborderline EOC, according to the recently updated AIOM (Associazione Italiana di Oncologia Medica)/SIGU (Società Italiana di Genetica Umana) /SIBIOC (Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica )/SIAPEC-IAP (Patologica e Citologia Diagnostica–italian division of International Academy of Pathology) guidelines [13] (Figure 3).